Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer

@article{Fleeman2014PertuzumabIC,
  title={Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer},
  author={Nigel Fleeman and Adrian Bagust and Sophie Beale and Kerry Dwan and Rumona Dickson and Christine Proudlove and Yenal Dundar},
  journal={PharmacoEconomics},
  year={2014},
  volume={33},
  pages={13-23}
}
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of pertuzumab (Roche) to submit evidence for the clinical and cost effectiveness of pertuzumab + trastuzumab + docetaxel for the treatment of human epidermal growth factor receptor 2-positive (HER2+) metastatic or locally recurrent unresectable breast cancer in accordance with the Institute’s Single Technology Appraisal (STA) process. The Liverpool Reviews and Implementation Group (LRiG) at the University of… 

Tables from this paper

Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
  • B. Durkee, Y. Qian, K. Horst
  • Medicine, Political Science
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
TLDR
Deterministic sensitivity analysis showed that THP in patients with metastatic HER2-positive breast cancer is unlikely to be cost effective in the United States, and probabilistic sensitivity analysis predicted 0% chance of cost effectiveness at a willingness to pay of $100,000 per QALY gained.
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.
TLDR
It is suggested that pertuzumab may increase survival for patients with metastatic breast cancer but would not be considered cost-effective, even after 100% price reduction, under conventional thresholds.
Pertuzumab in HER2-positive breast cancer: a guide to its use
TLDR
Pertuzumab significantly increased progression-free survival, objective response rate and overall survival relative to placebo when each was given in combination with trastuzumAB and docetaxel for the first-line treatment of HER2-positive metastatic/advanced breast cancer.
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects
TLDR
There is an urgent need for the development of predictive biomarkers for a better tailoring of anti-HER2 directed therapy to further improve clinical outcomes and quality of life and to decrease costs and toxicities of unnecessary treatments.
The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
TLDR
It is confirmed that pertuzumab is unable to inhibit HER2 homodimerization but induces HER2 phosphorylation at some pY sites that abolishes HER2 effects on cell cycle progress, and that pertizumab binding to HER2 may inhibit non-canonical HER2 activation and function in non-HER-mediated and dimerization-independent pathway(s).
Current-day precision oncology: from cancer prevention, screening, drug development, and treatment – have we fallen short of the promise?
TLDR
This review presents the successes, failures, and opportunities of precision oncology in the current landscape to give a realistic view of where the authors are, especially regarding cancer treatment and prevention.
Trastuzumab induces PUMA‐dependent apoptosis and inhibits tumor growth in gastric cancer
TLDR
Results indicate that trastuzumab induces PUMA‐dependent apoptosis and inhibits tumor growth in GC, suggesting that PUMA plays a critical role in mediating the antitumor effects of trastzumab in GC.
AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies
TLDR
Present data are in agreement with previous observations indicating that the engagement of the Epidermal Growth Factor Receptor by AvidinOX-bound biotinylated Cetuximab or Panitumumab, leads to potent tumor inhibition both in vitro and in animal models.
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics
TLDR
This review aims to briefly update polymorphic variations in genes encoding ErbB receptors based on recent advances in deep sequencing technologies, and to address challenging issues for a better understanding of the functional impact of single versus combined SNPs inErbB genes to receptor topology, receptor-drug interaction, and drug susceptibility.
...
1
2
...

References

SHOWING 1-10 OF 38 REFERENCES
S5-5: A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial To Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Patients with Previously Untreated HER2−Positive Metastatic Breast Cancer (CLEOPATRA).
TLDR
No increase in overall toxicity and, in particular, no increase in cardiac events was observed with the addition of P to H and HT regimens and the primary endpoint was progression-free survival as determined by independent review.
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
  • J. Baselga, K. Gelmon, L. Gianni
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
The combination of pertuzumsumab and trastuzumab is active and well tolerated in patients with metastatic HER2-positive breast cancer who had experienced progression during prior trastzumab therapy.
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
  • M. Marty, F. Cognetti, J. Extra
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
Tastuzumab combined with docetaxel is superior to docetAXel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity.
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
  • B. Kaufman, J. Mackey, A. Jones
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
Trastuzumab plus anastrozole improves outcomes for patients with HER2/hormone receptor-copositive MBC compared with anast rozole alone, although adverse events and serious adverse events were more frequent with the combination.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
TLDR
The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
TLDR
In patients with node-negative, HER2 positive, pT1a-b, pN0 breast cancer have a low risk of recurrence at 5 years of follow-up, and patients with hormone receptor-positive disease with HER2-positive status with a worse prognosis have a worse DFS.
Health state utilities for metastatic breast cancer
TLDR
This study underlines the value that society place on the avoidance of disease progression and severe side effects in MBC and may be the largest preference study in breast cancer designed to survey a representative general public sample.
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
TLDR
The review concludes with a consideration of HER-2 status in the prediction of response to non-HER-2 targeted treatments including hormonal therapy, anthracyclines, and taxanes.
P1-08-23: Characteristics of De Novo Stage IV Breast Cancer Presentation and Comparison with Stage IV Disease Relapse after Adjuvant Therapy.
TLDR
In this breast cancer patient cohort, there was a relatively high percentage of women presenting with stage IV disease, likely reflecting the underserved nature of this patient population, and women with de novo stage IV breast cancer were more likely to be older, have ER/PgR positive disease, and have bone metastasis as the primary site of involvement.
...
1
2
3
4
...